After leading diabetes and obesity drug discovery for 10 years at Merck, Moller moved to Lilly in 2006 because of the opportunity to broaden his therapeutic area experience to include ...

INDIANAPOLIS – Eli Lilly and Company says its obesity/pre-diabetes drug significantly reduces the risk of type 2 diabetes in certain adults and leads to sustained weight loss.

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...